Host Immune Response to Clostridium Difficile Infection (ICD)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Diarrhea Due to Clostridium Difficile

Treatments

Biological: Blood sampling

Study type

Interventional

Funder types

Other

Identifiers

NCT02440438
2013.806

Details and patient eligibility

About

Clostridium difficile is responsible for up to 25% of reported antibiotic associated diarrhea cases and virtually all cases of pseudomembranous colitis (PMC). The clinical spectrum of C. difficile infection (CDI) varies in severity from asymptomatic carriage to self-limited, mild, watery diarrhea, to PMC, intestinal perforation, toxic megacolon, sepsis, fulminant colitis, and death. In the past decade, the 027/NAP1/BI strain has emerged world-wide and has been implicated in large outbreaks with increased severity, frequent recurrence, and significant mortality. The host immune responses can influence the severity of CDI and play crucial roles in CDI onset, progression, and overall prognosis. Low serum concentrations of antibodies directed against the toxins A&B of C. difficile have been associated with a higher risk of recurrence. However, there are conflicting reports.

Enrollment

56 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Hospitalized
  • Suffering from diarrhea related to C. difficile
  • Confirmed diagnosis of CDI
  • Informed consent by the patient
  • Affiliated to the social security regime

Exclusion criteria

  • Out-patient
  • No confirmed diagnosis of CDI
  • Decline of participation
  • Patient not affiliated to the social security regime

Trial design

56 participants in 1 patient group

Clostridium difficile infection
Experimental group
Treatment:
Biological: Blood sampling

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems